Mitsubishi UFJ Asset Management Co. Ltd. Sells 3,174,080 Shares of Zoetis Inc. $ZTS

Mitsubishi UFJ Asset Management Co. Ltd. trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 74.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,070,271 shares of the company’s stock after selling 3,174,080 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Zoetis were worth $76,910,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Prosperity Bancshares Inc acquired a new position in shares of Zoetis during the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis in the 1st quarter valued at $28,000. Elyxium Wealth LLC acquired a new stake in Zoetis during the 4th quarter valued at $32,000. Root Financial Partners LLC lifted its holdings in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. Finally, Wellington Grp LLC boosted its position in Zoetis by 6,675.0% during the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

ZTS opened at $74.04 on Wednesday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The business has a fifty day simple moving average of $76.01 and a 200 day simple moving average of $98.13. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $160.48. The company has a market capitalization of $30.60 billion, a PE ratio of 12.20, a price-to-earnings-growth ratio of 1.28 and a beta of 0.73.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the business earned $1.76 EPS. The company’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts expect that Zoetis Inc. will post 6.2 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BNP Paribas Exane decreased their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Citigroup reduced their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Morgan Stanley set a $85.00 price target on shares of Zoetis in a research note on Friday, August 7th. Finally, Stifel Nicolaus lowered their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.